Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis

Table 1 Baseline characteristics of the study population (n = 127)

	No biliary candidiasis (n = 89)	Biliary candidiasis (n = 38)	P value
Age (mean ± SD), yr	58.3 ± 15.6	64.7 ± 15.0	< 0.05
Male/female	52/37	20/18	NS
Primary diagnosis			NS
Suspected carcinoma of the biliary tract	16 (18.0)	10 (26.3)
Stenosing papillitis	11 (12.4)	3 (7.9)
Carcinoma	9 (10.1)	6 (15.8)
PSC	9 (10.1)	5 (13.2)
CBD stenosis of unknown origin	13 (14.6)	5 (13.2)
Choledocholithiasis	9 (10.1)	3 (7.9)
Cholestatic hepatitis	4 (4.5)	1 (2.6)
Pancreatitis	4 (4.5)	-
Other	14 (15.7)	5 (13.2)
Indication for ERCP			NS
CBD stenosis	18 (20.2)	10 (26.3)
Suspected carcinoma	15 (16.9)	8 (21.1)
Carcinoma	9 (10.1)	6 (15.8)
Cholestasis	9 (10.1)	3 (7.9)
Choledocholithiasis	8 (9.0)	1 (2.6)
Cholangitis	7 (7.9)	2 (5.3)
PSC	6 (6.7)	5 (13.2)
Papillitis stenosans	4 (4.5)	-
Pancreatitis	2 (2.2)	-
Cholestatic hepatitis	1 (1.1)	1 (2.6)
Other	10 (11.2)	2 (5.3)

ERCP: Endoscopic retrograde cholangiopancreatography; CBD: Common bile duct; NS: Not significant; PSC: Primary sclerosing cholangitis; Other: Ischemic type biliary lesions, stenosis of the biliary anastomosis after liver transplantation, biliary cast syndrome, retroperitoneal fibrosis, iatrogenic injury of the bile duct, suspected primary or secondary sclerosing cholangitis.